Assess whether a CMO finding is a delay or a refuse-to-file risk (fbdb3a)

Situation

The CMC and Development Pathways desk packet is RWE protocol that may not meet regulator expectations after an FAERS cluster in a demographic the trials under-enrolled. CMC change-control owner in a rare-disease team designing a pediatric plan must name A CMO finding is a delay or A refuse-to-file risk for this Pharma & Life Sciences file. CMC change-control owner in a rare-disease team designing a pediatric plan has to name A CMO finding is a delay or A refuse-to-file risk for this Pharma & Life Sciences CMC and Development Pathways file.

Decision

CMC change-control owner in a rare-disease team designing a pediatric plan must choose A CMO finding is a delay / A refuse-to-file risk using RWE protocol that may not meet regulator expectations after an FAERS cluster in a demographic the trials under-enrolled.

Hypotheses to test

• The population in RWE protocol that may not meet regulator expectations is the one an FAERS cluster in a demographic the trials under-enrolled named, so A CMO finding is a delay follows for this CMC and Development Pathways file.
• The population in RWE protocol that may not meet regulator expectations is adjacent only to an FAERS cluster in a demographic the trials under-enrolled; A refuse-to-file risk is the honest Pharma & Life Sciences call.
• A rare-disease team designing a pediatric plan already contained an FAERS cluster in a demographic the trials under-enrolled before RWE protocol that may not meet regulator expectations arrived; no new CMC and Development Pathways path.
• Provenance on RWE protocol that may not meet regulator expectations after an FAERS cluster in a demographic the trials under-enrolled is broken; do not pick A CMO finding is a delay or A refuse-to-file risk yet.

Analysis required

• Trace CMC, labeling, or pharmacovigilance facts in RWE protocol that may not meet regulator expectations after an FAERS cluster in a demographic the trials under-enrolled.
• Separate an isolated adverse event from a systemic quality issue.
• Test a protocol deviation versus a safety signal versus a filing gap on a CMO finding is.
• For this Pharma & Life Sciences CMC and Development Pathways file, read RWE protocol that may not meet regulator expectations against an FAERS cluster in a demographic the trials under-enrolled and write the one fact that would move a CMO finding is for CMC change-control owner.